BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16785061)

  • 1. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
    Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
    Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies.
    Chang YJ; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.
    Kim DH; Sohn SK; Won DI; Lee NY; Suh JS; Lee KB
    Bone Marrow Transplant; 2006 Jun; 37(12):1119-28. PubMed ID: 16699530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation].
    Zhou Z; Wang M; He Y
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
    Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):471-82. PubMed ID: 19285635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
    van Heeckeren WJ; Fanning LR; Meyerson HJ; Fu P; Lazarus HM; Cooper BW; Tse WW; Kindwall-Keller TL; Jaroscak J; Finney MR; Fox RM; Solchaga L; Forster M; Creger RJ; Laughlin MJ
    Br J Haematol; 2007 Nov; 139(3):464-74. PubMed ID: 17910637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
    Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG
    Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.
    Yamasaki S; Ohno Y; Taniguchi S; Yoshida T; Hayashi S; Ogawa H; Shimazaki C; Takahashi S; Kasai M; Wake A; Nishimura M; Tokunaga K; Gondo H; Takaue Y; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Feb; 33(3):279-89. PubMed ID: 14647250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution following allogeneic peripheral blood stem cell transplants.
    Shenoy S; Mohanakumar T; Todd G; Westhoff W; Dunnigan K; Adkins DR; Brown RA; DiPersio JF
    Bone Marrow Transplant; 1999 Feb; 23(4):335-46. PubMed ID: 10100577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
    Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
    Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
    Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
    Cao TM; Wong RM; Sheehan K; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Negrin RS; Lowsky R
    Exp Hematol; 2005 Mar; 33(3):279-85. PubMed ID: 15730851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of graft compositions on hematopoietic reconstitution and graft-versus-host disease in related donor peripheral blood stem cell transplantation].
    Zhan Y; Yi ZS; Wei YQ; Huang F; Zhang YM; Fan ZP; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):333-6. PubMed ID: 18844073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.
    Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
    Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
    Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.